Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04061720
Other study ID # NURA-009-18F
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 12, 2019
Est. completion date September 30, 2025

Study information

Verified date November 2023
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project will generate knowledge about the effectiveness of Enhanced Chronic Care, an intervention designed to enhance treatment use and smoking abstinence in Veterans who are initially unwilling to quit. Enhanced Chronic Care provides ongoing motivational interventions and interpersonal support designed to promote readiness to quit smoking. Enhanced Chronic Care will be compared with Standard Care (brief advice to quit once per year) on criteria that are of great clinical and public health importance: use of cessation treatment and smoking abstinence. It is expected that Enhanced Chronic Care will increase treatment use and smoking abstinence relative to Standard Care.


Description:

This project will generate knowledge about the effectiveness of Enhanced Chronic Care, an intervention designed to enhance treatment use and smoking abstinence in Veterans who are initially unwilling to quit. Enhanced Chronic Care provides ongoing motivational interventions and interpersonal support designed to promote readiness to quit smoking. Enhanced Chronic Care will be compared with Standard Care (brief advice to quit once per year) on criteria that are of great clinical and public health importance: smoking treatment reach (use of cessation treatment) and abstinence. It is expected that Enhanced Chronic Care will increase treatment use and smoking abstinence relative to Standard Care. The investigators will evaluate these interventions using a 2-arm randomized controlled trial. Veterans who smoke daily, but who are not willing to enter smoking cessation treatment, will be eligible to participate, with no obligation to quit smoking. Participants (N=500) will be randomized to one of the following treatments: 1) Enhanced Chronic Care (n=250) or 2) Standard Care (n=250). These intervention conditions will last 2 years to permit analysis of their cumulative impact on abstinence and treatment use


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 502
Est. completion date September 30, 2025
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Not willing to set a quit date in the next 30 days - Report smoking an average of 4 or more cigarettes daily for at least six months - Read, write, and speak English - Be medically eligible to use nicotine replacement therapy - If female, use an approved method of birth control if they use nicotine replacement therapy - Agree to participate in the study - Be at least 18 years old - Be a Veteran Exclusion Criteria: - Unable to give informed, voluntary consent to participate - Current use of any pharmacotherapy for smoking cessation not provided by the researchers during tobacco treatment - Use of non-cigarette tobacco products as a primary form of tobacco use - Incarceration

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Enhanced Chronic Care
Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
Standard Care
Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.

Locations

Country Name City State
United States William S. Middleton Memorial Veterans Hospital, Madison, WI Madison Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
VA Office of Research and Development University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 7-Day Point-Prevalence Abstinence Participants who self-report no smoking for the past 7 days at the assessment endpoint (2-year follow-up) will be considered to meet criteria for 7-Day Point-Prevalence Abstinence. Participants who report any smoking in the past 7 days (at the 2 year follow-up) will be considered to be relapsed (smoking). 2 years
Secondary Initiating at least 1 cessation treatment call Cessation treatment use will be defined as making at least one treatment contact (initiating at least 1 cessation treatment call with reach coded as a binary outcome: use vs. no use). 2 years
See also
  Status Clinical Trial Phase
Completed NCT01928719 - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status N/A
Completed NCT01995123 - Behavioral Activation for Smoking Cessation in PTSD N/A
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Recruiting NCT02564289 - Cardiovascular Effects of Chronic Snus Use N/A
Completed NCT01928758 - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Recruiting NCT00977249 - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users Phase 2/Phase 3
Active, not recruiting NCT00968513 - Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry Phase 3
Completed NCT00747643 - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement N/A
Completed NCT00722124 - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Phase 2/Phase 3
Completed NCT01113424 - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum N/A
Completed NCT01238627 - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg N/A
Completed NCT01228617 - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products N/A
Completed NCT00296647 - Smoking Cessation Intervention: Effectiveness in Primary Care Phase 4
Completed NCT00394420 - Emergency Department Telephone Quitline N/A
Recruiting NCT05487807 - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia Phase 1
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A